177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
Kidney CancerHead and Neck Cancer7 moreThe purpose of this study is to evaluate changes in tumor blood flow and disease response to the investigation agent, 177Lu-J591.
Sorafenib in Treating Patients With Kidney Cancer That Has Spread to the Brain
Kidney CancerMetastatic CancerThis phase II trial is studying how well sorafenib works in treating patients with kidney cancer that has spread to the brain. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma
Breast CancerKidney Cancer6 moreRATIONALE: Interferon alfa may interfere with the growth of cancer cells and slow the growth of cancer. PURPOSE: This phase I trial is studying the side effects and best dose of interferon alfa in treating patients with stage IV solid tumors, lymphoma, or myeloma.
Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer
Kidney CancerRATIONALE: Biological therapy such as lenalidomide use different ways to stimulate the immune system and stop tumor cells from growing. It may also stop the growth of tumor cells by stopping blood flow to the tumor. PURPOSE: This phase II trial is studying how well lenalidomide works in treating patients with advanced or unresectable kidney cancer.
Vaccine Therapy in Treating Patients With Kidney Cancer
Kidney CancerRATIONALE: Vaccines made from DNA may make the body build an immune response to kill tumor cells. PURPOSE: This randomized phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with kidney cancer.
Monoclonal Antibody Therapy in Treating Patients With Metastatic Renal Cell Cancer
Kidney CancerRATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody therapy in treating patients who have metastatic renal cell cancer (kidney cancer) that is refractory to treatment with interleukin-2 or unable to be treated with interleukin-2.
Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell...
Kidney CancerRATIONALE: Tretinoin may help cells that are involved in the body's immune response to work better. Interleukin-2 may stimulate the white blood cells to kill kidney cancer cells. Giving tretinoin together with interleukin-2 may kill more tumor cells. PURPOSE: This randomized phase II trial is studying how well giving three different doses of tretinoin together with interleukin-2 works in treating patients with stage IV kidney cancer.
Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract
Metastatic Transitional Cell Cancer of the Renal Pelvis and UreterRecurrent Bladder Cancer5 moreThis phase II trial is studying how well sorafenib works in treating patients with advanced or metastatic cancer of the urinary tract. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
A Safety, Tolerability and Efficacy Study of E7070 in Patients With Renal Cell Carcinoma
Kidney NeoplasmsCarcinoma3 moreThe purpose of this study is to determine if E7070 is a safe and effective treatment for cancer of the kidneys.
Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer...
Recurrent Bladder Urothelial CarcinomaRecurrent Renal Pelvis Urothelial Carcinoma18 moreThis phase II trial studies how well erlotinib hydrochloride works in Treating participants with muscle invasive urothelial cancer or urothelial cancer that has come back. Drugs used in chemotherapy, such as erlotinib hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.